Intercepting Cancer When DNA Surveillance Fails

About this episode

Marina Udier discusses Nouscom's approach to developing cancer vaccines that train the immune system to detect and eliminate cancer cells early.

Many people with the genetic condition Lynch syndrome live with the near‑certainty that they will one day develop cancer and have few options beyond constant screening and, in some cases, preventive surgery. Nouscom is trying to change that by training the immune system to spot and destroy cancer cells before tumors ever form. We spoke to Marina Udier, CEO of Nouscom, about the company’s experimental cancer vaccines, how they work, and the broader potential for the company’s off‑the‑shelf cancer therapies.

People in this episode

Guest: Marina Udier

Topics covered

• cancer
• immune system
• Lynch syndrome
• experimental vaccines
• preventive surgery

Keywords

• cancer
• Lynch syndrome
• Nouscom
• immune system
• vaccines
• preventive surgery
• tumors

Mentioned in this episode

Organizations: Nouscom, Lynch syndrome

More episodes of The Bio Report

• Stopping Shape-Shifting Tumors with a First-in-Class Epigenetic Drug · June 10, 2026 · 28 min
• Rewriting the Rules of Antibody Drug Design · June 3, 2026 · 38 min
• Mapping Cellular Stress Biology to Tackle Undruggable Targets · May 27, 2026 · 30 min
• Turning Abandoned Drugs into Breakthroughs · May 20, 2026 · 31 min
• Targeting Cancer Survival Genes in Solid Tumors · May 13, 2026 · 46 min
• Addressing Treatment Gaps in Gout · May 6, 2026 · 37 min